Company profile MIRM
After 38 days of this quarter the interest is at 106.0. Based on that we can calculate that during remaining 53 days it will total up to 254.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 140 | 210 50.0% QoQ | 217 3.3% QoQ | 132 -39.2% QoQ |
| 2020 | 246 75.7% YoY 86.4% QoQ | 70 -66.7% YoY -71.5% QoQ | 227 4.6% YoY 224.3% QoQ | 295 123.5% YoY 30.0% QoQ |
| 2021 | 360 46.3% YoY 22.0% QoQ | 192 174.3% YoY -46.7% QoQ | 356 56.8% YoY 85.4% QoQ | 254 -13.9% YoY -28.7% QoQ |
| 2022 | 195 -45.8% YoY -23.2% QoQ | 129 -32.8% YoY -33.8% QoQ | 262 -26.4% YoY 103.1% QoQ | 147 -42.1% YoY -43.9% QoQ |
| 2023 | 258 32.3% YoY 75.5% QoQ | 314 143.4% YoY 21.7% QoQ | 306 16.8% YoY -2.5% QoQ | 365 148.3% YoY 19.3% QoQ |
| 2024 | 106 -58.9% YoY -71.0% QoQ | - | - | - |
The average 5 years interest of Mirum Pharmaceuticals was 18.32 per week. The last year interest of Mirum Pharmaceuticals compared to the last 5 years has changed by 34.28%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 61.95%.
There is not enough data for Mirum Pharmaceuticals news to provide analysis
There is not enough data for Mirum Pharmaceuticals news to provide correlation calculation
There is not enough data for Mirum Pharmaceuticals news to provide analysis
There is not enough data for LIVMARLI treatment to provide analysis
There is not enough data for LIVMARLI treatment to provide correlation calculation
There is not enough data for LIVMARLI treatment to provide analysis
There is not enough data for Alagille syndrome treatment to provide analysis
There is not enough data for Alagille syndrome treatment to provide correlation calculation
There is not enough data for Alagille syndrome treatment to provide analysis
After 38 days of this quarter the interest is at 105.0. Based on that we can calculate that during remaining 53 days it will total up to 251.0. biliary atresia treatment expected interest is significantly higher compared to previous quarter (+286.2%) and same quarter last year (+1830.8%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 6 | 37 516.7% QoQ | 10 -73.0% QoQ | 31 210.0% QoQ |
| 2020 | 17 183.3% YoY -45.2% QoQ | 33 -10.8% YoY 94.1% QoQ | 35 250.0% YoY 6.1% QoQ | 45 45.2% YoY 28.6% QoQ |
| 2021 | 29 70.6% YoY -35.6% QoQ | 57 72.7% YoY 96.6% QoQ | 20 -42.9% YoY -64.9% QoQ | 30 -33.3% YoY 50.0% QoQ |
| 2022 | 40 37.9% YoY 33.3% QoQ | 35 -38.6% YoY -12.5% QoQ | 43 115.0% YoY 22.9% QoQ | 13 -56.7% YoY -69.8% QoQ |
| 2023 | 13 -67.5% YoY 0.0% QoQ | 29 -17.1% YoY 123.1% QoQ | 45 4.7% YoY 55.2% QoQ | 65 400.0% YoY 44.4% QoQ |
| 2024 | 105 707.7% YoY 61.5% QoQ | - | - | - |
The average 5 years interest of biliary atresia treatment was 2.83 per week. The last year interest of biliary atresia treatment compared to the last 5 years has changed by 74.56%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 182.29%.
There is not enough data for Volixibat treatment to provide analysis
There is not enough data for Volixibat treatment to provide correlation calculation
There is not enough data for Volixibat treatment to provide analysis
After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0. primary sclerosing cholangitis treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 139 | 218 56.8% QoQ | 120 -45.0% QoQ | 97 -19.2% QoQ |
| 2020 | 190 36.7% YoY 95.9% QoQ | 58 -73.4% YoY -69.5% QoQ | 112 -6.7% YoY 93.1% QoQ | 71 -26.8% YoY -36.6% QoQ |
| 2021 | 106 -44.2% YoY 49.3% QoQ | 243 319.0% YoY 129.2% QoQ | 58 -48.2% YoY -76.1% QoQ | 159 123.9% YoY 174.1% QoQ |
| 2022 | 24 -77.4% YoY -84.9% QoQ | 112 -53.9% YoY 366.7% QoQ | 148 155.2% YoY 32.1% QoQ | 148 -6.9% YoY 0.0% QoQ |
| 2023 | 51 112.5% YoY -65.5% QoQ | 134 19.6% YoY 162.7% QoQ | 219 48.0% YoY 63.4% QoQ | 147 -0.7% YoY -32.9% QoQ |
| 2024 | 0 -100.0% YoY -100.0% QoQ | - | - | - |
The average 5 years interest of primary sclerosing cholangitis treatment was 9.79 per week. The last year interest of primary sclerosing cholangitis treatment compared to the last 5 years has changed by 8.27%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -10.55%.
After 39 days of this quarter the interest is at 117.0. Based on that we can calculate that during remaining 52 days it will total up to 273.0. primary biliary cholangitis treatment expected interest is significantly higher compared to previous quarter (+295.7%) and same quarter last year (+71.7%).
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 68 | 60 -11.8% QoQ | 98 63.3% QoQ | 74 -24.5% QoQ |
| 2020 | 35 -48.5% YoY -52.7% QoQ | 101 68.3% YoY 188.6% QoQ | 136 38.8% YoY 34.7% QoQ | 85 14.9% YoY -37.5% QoQ |
| 2021 | 130 271.4% YoY 52.9% QoQ | 65 -35.6% YoY -50.0% QoQ | 121 -11.0% YoY 86.2% QoQ | 169 98.8% YoY 39.7% QoQ |
| 2022 | 173 33.1% YoY 2.4% QoQ | 105 61.5% YoY -39.3% QoQ | 137 13.2% YoY 30.5% QoQ | 102 -39.6% YoY -25.5% QoQ |
| 2023 | 159 -8.1% YoY 55.9% QoQ | 139 32.4% YoY -12.6% QoQ | 85 -38.0% YoY -38.8% QoQ | 69 -32.4% YoY -18.8% QoQ |
| 2024 | 117 -26.4% YoY 69.6% QoQ | - | - | - |
The average 5 years interest of primary biliary cholangitis treatment was 8.54 per week. The last year interest of primary biliary cholangitis treatment compared to the last 5 years has changed by 12.41%. This is something to be checked. The last year interest is quite higher compared to 5 years ago. It has increased by 56.61%.
After 38 days of this quarter the interest is at 66.0. Based on that we can calculate that during remaining 53 days it will total up to 158.0. Mirum Pharmaceuticals stock expected interest is significantly higher compared to same quarter last year (+887.5%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 62 | 121 95.2% QoQ | 186 53.7% QoQ | 112 -39.8% QoQ |
| 2020 | 126 103.2% YoY 12.5% QoQ | 100 -17.4% YoY -20.6% QoQ | 19 -89.8% YoY -81.0% QoQ | 24 -78.6% YoY 26.3% QoQ |
| 2021 | 160 27.0% YoY 566.7% QoQ | 104 4.0% YoY -35.0% QoQ | 231 1115.8% YoY 122.1% QoQ | 104 333.3% YoY -55.0% QoQ |
| 2022 | 64 -60.0% YoY -38.5% QoQ | 29 -72.1% YoY -54.7% QoQ | 115 -50.2% YoY 296.6% QoQ | 85 -18.3% YoY -26.1% QoQ |
| 2023 | 16 -75.0% YoY -81.2% QoQ | 107 269.0% YoY 568.8% QoQ | 105 -8.7% YoY -1.9% QoQ | 181 112.9% YoY 72.4% QoQ |
| 2024 | 66 312.5% YoY -63.5% QoQ | - | - | - |
The average 5 years interest of Mirum Pharmaceuticals stock was 8.11 per week. The last year interest of Mirum Pharmaceuticals stock compared to the last 5 years has changed by 12.58%. This is something to be checked. The last year interest is comparable to 5 years ago. It has changed only by -13.21%.